Chromocell raises $750k via convertible note and secures $30M committed equity facility

Pelthos Therapeutics Inc.

$750k convertible note issued, 6% interest (12% default), convertible at $1.506/share, floor $0.231, maturity Aug 24, 2025.
Committed equity facility with Tikkun Capital for up to $30M; shares sold at 90% of VWAP over up to 24 months.
$750k commitment fee paid to Tikkun; $75k legal fees reimbursed; restrictions on variable rate transactions.
Stockholder approval required to exceed exchange cap; meeting within 90 days for note; similar cap for equity facility.
Proceeds to fund clinical work on CC8464 and CT2000 compounds and for working capital and general corporate purposes.

item 1.01 item 2.03 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.